PDF Archive

Easily share your PDF documents with your contacts, on the Web and Social Networks.

Share a file Manage my documents Convert Recover PDF Search Help Contact


Search


PDF Archive search engine
Last database update: 25 September at 17:59 - Around 220000 files indexed.

Show results per page

Results for «metastatic»:


Total: 70 results - 0.056 seconds

cvfile 0023229 100%

PALLIATIVE CARE THE KOREAN SOCIETY OF HEMATOLOGY KOREAN CANCER STUDY GROUP KOREAN ASSOCIATION FOR CLINICAL ONCOLOGY CLINICAL TRIAL EXPERIENCE - A Phase III, randomized, Double-blind, Placebo-Controlled, Multicenter study to evaluate the efficacy and safety of Bevacizumab, and Associcated Biomarkers, in combination with Paclitaxel compared with Paclitaxel plus Placebo as 1st line Treatment of patients with HER2-Negative Metastatic Breast cancer, sponsored by Roche, 2013, Principal investigator [GO25632] - A Multi-national Phase III Clinical Study Comparing NK105 Versus Paclitaxel in Patients with Metastatic or Recurrent Breast Cancer, sponsored by Nippon Kayaku, 2013, Principal investigator [NK105] - A Phase 3 Open-label, Randomized, Multicenter study of NKTR-102 versus Treatment of physician’s choice(TPC) in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine, sponsored by Nektar, 2013, sub-investigator [BEACON] - A Phase 2 Randomized Trial of the Combination of Ridaforolimus and Exmestane, Compared to Ridaforolimus, Dalotuzumab and Exmestane in High Proliferation Estrogen Receptor Positive Breast Cancer Patients.

https://www.pdf-archive.com/2015/07/05/cvfile-0023229/

05/07/2015 www.pdf-archive.com

v15n4S 57Revisiting 99%

2012;15(Suppl):S57-63 REVIEW ARTICLE Revisiting the Role of Anti-angiogenesis Therapy in Metastatic Breast Cancer CH Kwok Department of Oncology, Princess Margaret Hospital, Hong Kong ABSTRACT Angiogenesis is essential for tumour growth and metastasis, and constitutes an important process in the control of cancer progression.

https://www.pdf-archive.com/2019/04/11/v15n4s57revisiting/

11/04/2019 www.pdf-archive.com

ADCs for Clinical Research in the Global Market 97%

HER2/neu ph2 ADC Therapeutics CD19 ph2 relapsed or refractory DLBCL ADC Therapeutics CD25 ph2 Hodgkin lymphoma AbbVie c-met ph2 NSCLC 6SK BCMA ph2 Multiple myeloma Roche LIV1 Ph1/2 Triple Negative Breast Cancer(TNBC) Daiichi Sankyo HER3 Ph1/2 BMS-986148 BMS mesothelin Ph1/2 solid tumor enapotamab Seattle Genetics AXL Ph1/2 solid tumor mirvetuximab soravtansine trastuzumab duocarmazine trastuzumab Bio-Thera maytansine Solutions anetumab ravtansine tisotumab vedotin Remegen RC48 loncsstuximab tesirine camidanlumab tesirine telisotuzumab vedotin belantamab mafodotin ladiratuzumab vedotin patritumab deruxtecan HER2 positive metastatic breast cancer HER2 positive metastatic breast cancer pancreatic cancer ovarian cancer HER2 positive metastatic breast cancer HER3 positive metastatic breast cancer https://www.biochempeg.com Biochempeg Scientific Inc.

https://www.pdf-archive.com/2020/02/28/adcs-for-clinical-research-in-the-global-market/

28/02/2020 www.pdf-archive.com

Aarkstore - Lonsurf (Colorectal Cancer) 2023 91%

This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic.

https://www.pdf-archive.com/2015/05/21/aarkstore-lonsurf-colorectal-cancer-2023/

21/05/2015 www.pdf-archive.com

CDK46 Inhibitors for Treatment of Advanced Breast Cancer 90%

The majority of patients with metastatic breast cancer (MBC) have hormone receptor-positive HER2-negative disease.

https://www.pdf-archive.com/2019/12/27/cdk46-inhibitors-for-treatment-of-advanced-breast-cancer/

27/12/2019 www.pdf-archive.com

FDA Approves Sacituzumab Govitecan for Triple-Negative Breast Cancer 88%

Biochempeg https://www.biochempeg.com FDA Approves Sacituzumab Govitecan for Triple-Negative Breast Cancer On April 22, 2020, the FDA has granted an accelerated approval to the antibody-drug conjugate (ADC) sacituzumab govitecan-hziy (Trodelvy, Immunomedics, Inc.) for the treatment of adult patients with metastatic triple-negative breast cancer (TNBC) who have received at least 2 prior therapies for metastatic disease.

https://www.pdf-archive.com/2020/04/29/untitled-pdf-document/

29/04/2020 www.pdf-archive.com

32nd Consensus Conference 87%

박영석(성균관의대), 오상철(고려의대) 14:30-14:55 25min Immunotherapy for MSI-High Metastatic Colorectal Cancer 14:55-15:20 25min Approaches to MSS-Metastatic CRC 15:20-15:30 10min Q&A Cutting Edge of the Treatment of Metastatic Colorectal Cancer 김선영(울산의대) 임유주(서울의대) 김승태(성균관의대) 좌장 :

https://www.pdf-archive.com/2018/04/06/32nd-consensus-conference/

06/04/2018 www.pdf-archive.com

2017DBS Antibody Flyer 102017 web 87%

NKX3.1 NKX3.1 may prove to be a valuable marker to assist in determining prostatic origin in poorly differentiated metastatic carcinomas.

https://www.pdf-archive.com/2017/10/30/2017dbs-antibody-flyer-102017-web/

30/10/2017 www.pdf-archive.com

Kasi - Vittal Poster - Final 86%

A Rare Case Report Of Coexisting Mutually Exclusive KRAS And BRAF Mutations In A Patient With Metastatic Colon Adenocarcinoma Anusha Vittal MBBS 1, Anup Kasi Loknath Kumar MD, MPH 2 1 Department of Internal Medicine, 2 Division of Medical Oncology, University of Kansas Medical Center, Kansas City, KS Abstract Discussion Background:

https://www.pdf-archive.com/2016/04/29/kasi-vittal-poster-final/

29/04/2016 www.pdf-archive.com

May June 2017 (1) 84%

6-8 pm 7 Metastatic Group 10 am-12 pm Yoga 11 am-12:15 pm Sit &

https://www.pdf-archive.com/2017/04/24/may-june-2017-1/

24/04/2017 www.pdf-archive.com

NCCN melanoma guidelines 84%

NCCN Guidelines Version 3.2015 Table of Contents Melanoma NCCN Melanoma Panel Members Summary of the Guidelines Updates Clinical Presentation and Preliminary Workup (ME-1) Stage 0 (in situ), Stage IA (ME-2) Stage IB, Stage II (ME-3) Stage III (ME-4) Stage III In-Transit (ME-5) Stage IV Metastatic (ME-6) Follow-up (ME-7) Persistent Disease or True Local Scar Recurrence;

https://www.pdf-archive.com/2015/09/17/nccn-melanoma-guidelines/

17/09/2015 www.pdf-archive.com

2016.01.04 08-10-48Reena Nair cv 2016 84%

10951 (Amendment n2) titled as “Randomized phase II - III study in first line hormonal treatment for metastatic breast cancer with EORTC Exemestane or Tamoxifen in Postmenopausal patients".

https://www.pdf-archive.com/2018/09/11/2016010408-10-48reena-nair-cv-2016/

11/09/2018 www.pdf-archive.com

2nd MBC Summit Report 2017 final 83%

The 2nd MBC Summit....................................................................................................................................6 Metastatic Breast Cancer........................................................................................................................

https://www.pdf-archive.com/2017/12/25/2nd-mbc-summit-report-2017-final/

25/12/2017 www.pdf-archive.com

cvfile 0023228 82%

Phase III, Multicenter, Randomized Trial of Maintenance Chemotherapy Versus Observation in Patients With Metastatic Breast Cancer After Achieving Disease Control With Six Cycles of Gemcitabine Plus Paclitaxel As First-Line Chemotherapy:

https://www.pdf-archive.com/2015/05/10/cvfile-0023228/

10/05/2015 www.pdf-archive.com

ER0949 81%

Xynos (Heraklion) Anal Squamous Cell Cancer Surgical Anatomy of Transverse Colon Liver Metastatic Disease Radiomics Unresectable-to-Resectable Conversion Neo-Adjuvant Treatment for Locally Advanced Disease Increasing Resectability Rates Immunotherapy Management of Synchronous CRC Surgical Treatment:

https://www.pdf-archive.com/2018/03/08/er0949/

08/03/2018 www.pdf-archive.com

30th Consensus Conference 80%

사전등록 마감 The Best Care of Metastatic Breast Cancer :

https://www.pdf-archive.com/2018/04/06/30th-consensus-conference/

06/04/2018 www.pdf-archive.com

JDIT-2014-1007-004 77%

16α-[18F]Fluoro-17β-estradiol (18F-FES) has proven to be a promising tracer for in vivo imaging studies of the ER status of primary and metastatic breast cancer.

https://www.pdf-archive.com/2017/05/30/jdit-2014-1007-004/

30/05/2017 www.pdf-archive.com

Protocols List - Clinical Research Program 76%

Stanimir -McG 0010- (98-6475-183) A Ran domized, Open-Label, M ulticenter, Phase Ill Study St udy Comparing t he Efficacy and Safety of Gemcitabine and lrenotecan HCI (CPT-11) to t he Gemcita bine Alon e in Patients w ith Locally Advanced or Metastatic Pancreat ic Cancer who Have Not Received Prior Systemic Therapy Pharmacia TERM INATED (Dr.

https://www.pdf-archive.com/2016/09/09/protocols-list-clinical-research-program/

09/09/2016 www.pdf-archive.com

28th Consensus Conference 76%

metastatic RCC 좌장:

https://www.pdf-archive.com/2018/04/06/28th-consensus-conference/

06/04/2018 www.pdf-archive.com

ER1107 76%

current status of systemic treatment in advanced and metastatic stage:

https://www.pdf-archive.com/2018/09/11/er1107/

11/09/2018 www.pdf-archive.com

Urology Congress Programme 75%

Medical treatment for advanced and metastatic PCa David Quinn 15.50 – 18.00 Live surgeries 1.

https://www.pdf-archive.com/2016/05/02/urology-congress-programme/

02/05/2016 www.pdf-archive.com

26th Consensus Conference 74%

Optimal chemotherapy after curative surgical resection of metastatic colorectal cancer 이명아 (가톨릭의대) 김정호 (서울의대) 40,000원 기타, 업체 참가 50,000원 60,000원 김승태 (성균관의대) 좌장 :

https://www.pdf-archive.com/2018/04/06/26th-consensus-conference/

06/04/2018 www.pdf-archive.com

Never Flinch Registration 74%

Weston Johnson, a former football player for the University of Wyoming and the current assistant football coach at Sheridan High School has recently been diagnosed with metastatic cancer.

https://www.pdf-archive.com/2013/04/03/never-flinch-registration/

03/04/2013 www.pdf-archive.com

cv-pantel 74%

Dissecting the metastatic cascade in cancer patients” Organization of International Meetings and Workshops:

https://www.pdf-archive.com/2018/03/19/cv-pantel/

19/03/2018 www.pdf-archive.com

14072 74%

Pretesh Patel, MD UPDATE ON SYSTEMIC THERAPY FOR METASTATIC GASTRIC/GASTROESOPHAGEAL CANCERS Christina Wu, MD Q&A Mihir Shah, MD (Moderator) COFFEE BREAK AND MEET EXHIBITORS SESSION 2 HEPATOBILIARY MALIGNANCIES 10:05-10:20 CHOLANGIOCARCINOMA:

https://www.pdf-archive.com/2019/08/07/14072/

07/08/2019 www.pdf-archive.com